STAT+: The Boston area built a ton of lab space. Now many of those buildings are opening empty
Around this time three years ago, while most of us navigated pandemic life, real estate developers…
Category: Boston
STAT+: A ‘vaccine-like’ version of Wegovy is on the drawing board at Novo Nordisk
LEXINGTON, Mass. — New obesity drugs like Wegovy and Zepbound are currently taken once a…
STAT+: Bipartisan group of lawmakers warns of a rising Chinese threat to U.S. biotech
CAMBRIDGE, Mass. — The increasingly adversarial relationship between the United States and China has raised…
STAT+: Pear Therapeutics dreamt of huge revenues and ‘commercial scale.’ It never came close
In January, Pear Therapeutics was quickly running out of money. The digital health startup embarked…
‘The hospital never supported the midwives’: As more birth centers open, their viability hinges on nearby hospitals
BEVERLY, Mass. — It was fitting, one activist said, that the sky was storming on…
‘People count on it’: In Boston, a mobile clinic meets health needs in the neighborhood
BOSTON — By 9 a.m. on a recent Friday morning, the bright blue, colorfully branded…
STAT+: Merck, a loser in the Covid vaccine race, reinvests in mRNA through a Cambridge startup
Among the most notable aspects of the Covid-19 vaccine race was who won it: Pfizer…
STAT+: Amid Aduhelm woes, Biogen moves to pare back office space
Biogen is moving to scale back its real estate footprint in Kendall Square and in Weston,…
STAT+: Can Biogen’s backup plan for Alzheimer’s succeed?
Everyone needs a backup plan, including one of the biggest biotech companies in town. So…
Lattes and gummies: Food science inspires a new approach to treating gut and liver injury
Inspired by how coffee shops foam milk, as well as gummy candy and sizzling Pop…
He had an M.D. and a Ph.D. but didn’t match into a residency. It was the push he needed to jump into health tech
Travis Hughes had been assured by both mentors and peers that he was a front-runner…
STAT+: Private equity firms to acquire Athenahealth for $17 billion
Athenahealth, the Watertown-based electronic health records company, said Monday that it will be acquired for…
STAT+: As scientific labs replace offices, pushback is mounting from wary neighbors
The rapid growth of biotech labs in Greater Boston might end up saving the region’s…
STAT+: MIT professor sues after he was forced to resign from institute following sexual harassment allegations
A prominent Massachusetts Institute of Technology biology professor who was forced two months ago to resign from…
Sex of the fetus influences the mother’s response to Covid-19 infection, new research shows
In April 2020, as SARS-CoV-2 was first beginning to spread through New England, researchers at…
A new surgical robot is smaller, nimbler, and cheaper, its maker claims. But will it be better for patients?
The surgical robot market, long dominated by one company, has a new entrant hoping to…
STAT+: Graduate students launch an entrepreneurship program to bring new faces to biotech
A group of graduate students is expanding a Boston-based biotech entrepreneurship program across the country,…
Biogen admits Aduhelm launch ‘slower than we anticipated’
Biogen CEO Michel Vounatsos admitted Thursday that the launch of Aduhelm, the company’s intensely scrutinized…
STAT+: Boston Scientific completes $1 billion acquisition of Israeli firm
Boston Scientific’s shopping spree for smaller medical-device companies continued on Wednesday when the Marlborough-based company…
‘Remember her as the badass she was’: ALS patient who died should force Biogen, others to anticipate expanded access issues
It’s been two weeks since Lisa Stockman Mauriello passed away and a lingering question, in…
STAT+: Adagio raises $300 million in IPO, looks to advance Covid-19 antibody therapy
Adagio Therapeutics, a Waltham startup advancing COVID-19 antibody treatments, is going public Friday just over…
STAT+: Amylyx is breaking all of biotech’s unwritten rules — and still raising impressive sums
If you want to raise big money in biotech, there are a few unwritten rules….
How a 3D-printed graft could speed healing of ruptured eardrums
In the weeks that followed the 2013 Boston Marathon bombing, doctors saw a flood of…
How a new buddy system is helping health workers grapple with Covid’s toll
Sylvia Perry had mainly worked in primary care before the Covid-19 pandemic hit. But as…
STAT+: What’s next for the new Alzheimer’s drug? Lots of thorny issues ahead
Despite all the excitement surrounding the FDA’s approval on Monday of a controversial treatment for Alzheimer’s disease, the…
STAT+: German drug maker Morphosys to buy Constellation Pharma in $1.7 billion deal
German drugmaker MorphoSys said Wednesday that it will acquire Constellation Pharmaceuticals for $1.7 billion to…
Aiming to diversify science journalism, STAT creates fellowship named for reporter Sharon Begley
STAT on Tuesday opened applications for a new early-career science journalism fellowship named in memory…
STAT+: Mass. governor’s role in Covid-19 tragedy at the Holyoke Soldiers’ Home
This story first appeared in STAT’s sister publication, the Boston Globe. It was reported by…
STAT+: Atlas Venture launches another biotech to tackle vision loss
Call it “Quest for Sight: The Sequel.” In September, the Swiss drug giant Novartis paid…
STAT+: Inside Pear’s ambitious plan to become the most dominant player in digital therapeutics
In the last six months, Pear Therapeutics has raised $100 million, inked a bevy of new…
STAT+: Moderna’s CEO says he ‘didn’t lose a minute of sleep’ over potential waiver of vaccine patents
Moderna chief executive Stephane Bancel on Thursday shrugged off the Biden administration’s support for suspending…
STAT+: Dyno raises $100 million to bring artificial intelligence to gene therapy
Dyno Therapeutics, a Cambridge biotech that uses artificial intelligence techniques to develop gene therapies, said…
STAT+: Adagio raises $336 million to advance Covid-19 antibody treatment
Waltham-based Adagio Therapeutics announced on Monday that it has raised $336 million in new funding…
STAT+: Thermo Fisher buys contract-research company PPD for $17.4 billion
Thermo Fisher Scientific announced Thursday that it will buy PPD, a contract-research company for the…
STAT+: Tango Therapeutics to go public in $353 million SPAC deal
Cambridge biotech Tango Therapeutics is going public through a $353 million deal with a special…
A deathbed double standard: It’s hard to get released on medical parole — unless you’re about to become a Covid-19 statistic
During his 39 years in prison, the closest Joseph Messere ever came to walking free…
‘As good a model as I’ve seen’: MIT biologist on new initiative to address gender inequities in biotech
When Nancy Hopkins joined the faculty of the Massachusetts Institute of Technology nearly 50 years…
STAT+: Massachusetts General Hospital president Peter Slavin to depart after 18 years
The president of Massachusetts General Hospital, Dr. Peter L. Slavin, plans to step down after…
STAT+: MIT scientists launch Future Founders Initiative to solve biotech’s ‘missing women’ problem
A group of prominent MIT scientists that formed to address gender inequities in the biotech…
STAT+: Boston’s hospital chiefs moonlight on corporate boards at rates far beyond the national level
As chief of Boston Children’s Hospital, one of the most esteemed pediatric hospitals in the…
STAT+: The Broad Institute’s new leader wants to ‘double down’ on biology
It has been an action-packed pandemic for the Broad Institute, the biomedical research center in…
STAT+: FDA delays approval decision for Biogen’s Alzheimer’s treatment
The Food and Drug Administration is delaying its decision on Biogen’s closely watched Alzheimer’s drug…
STAT+: After Moderna’s medical miracle, some investors step back
Moderna performed a miracle last year: The Cambridge biotech company, which hadn’t put a product…
STAT+: ‘What was left for Haven?’: How Amazon’s health ambitions devoured Haven’s plans
It’s tempting to see Haven as another casualty of entrenched interests in American medicine. But…
STAT+: With biotech funding at ‘all-time high,’ Scorpion scoops up $162 million
Just over two months after announcing its debut with $108 million in funding, Boston startup…
Opinion: STAT+: ‘There are a lot of potential Modernas’: The ‘Massachusetts Miracle’ is alive and well
With the Moderna vaccine, Massachusetts is having a moment. Ours is a story not about…
.jpg)
STAT+: New biotech backed by Third Rock launches with $81 million to go after ALS, other diseases
A new biotechnology company was launched Thursday in Cambridge with $81 million in funding, joining…
STAT+: Federal watchdog urged to investigate the FDA’s handling of Biogen Alzheimer’s drug
A federal watchdog is being asked to investigate the Food and Drug Administration for an…
STAT+: Alnylam wins FDA approval for first drug to treat rare kidney disease
Alnylam Pharmaceuticals Inc. scored its third approval from the US Food and Drug Administration in…
STAT+: A new startup wants to use natural killer cells to fight cancer
On a blustery day last December, five biotech entrepreneurs and scientists walked past the snow-draped…